Skip to main content

Table 1 Old and new drugs tested or used in the oncological setting and potentially useful in COVID-19 therapy

From: Drug repurposing against COVID-19: focus on anticancer agents

Drug MoA
Rapamycin and derivatives Immunosuppressant; PI3K/mTOR inhibitor; inhibitor of viral replication
Chloroquine and derivatives Antimalarial; broad spectrum anti-infective agent; interferent with protein post-translational processes; autophagy inhibitor; MAPK inhibitor; inhibitor of pro-inflammatory cytokines
SI113 SGK1 inhibitor
Tocilizumab MoAb targeting IL-6R, thus contrasting cytokine storm and fibrotic degeneration
Sarilumab MoAb targeting IL-6R, thus contrasting cytokine storm and fibrotic degeneration
Emapalumab plus anakinra MoAb targeting IFN-γ plus IL-1R antagonist
Monalizumab MoAb targeting NKG2A
BCG Tuberculosis prevention; inhibition of a TGF-β1-mediated EMT
Lopinavir plus ritonavir Viral Protease inhibitors approved for HIV treatment
Ribavirin Viral RNA synthesis inhibitor; RdRp inhibitor
Remdesivira Viral RNA polymerase inhibitor
  1. BCG Bacillus Calmette-Guérin, EMT Epithelial-to-mesenchymal transition; MoA Mechanism of Action; MoAb Mono- clonal antibody; RdRp RNA-dependent RNA polymerase
  2. aNot used in oncological settings